J&J’s tau-targeting antibody fails Phase 2 Alzheimer's study
#fails Phase#Alzheimer study#study Johnson#early-stage disease#promising candidates
Life Science News
Latest updates from the biotech and pharma world
Kelun's TROP2 ADC plus Keytruda improves outcomes in first-line lung cancer
#first-line lung#lung cancer#cancer Merck#Keytruda improves#Chinese regulatory
Sarepta to pay $200M milestone to Arrowhead; Enlivex reports osteoarthritis data
#Clearside Biomedical#MindImmune Therapeutics#Enlivex reports#pay Arrowhead#continues type
Biogen pens I&I deal with new Versant macrocycle developer Dayra Therapeutics
#Versant Ventures’#Dayra Therapeutics#Ventures’ latest#Therapeutics Versant#Versant macrocycle
Bayer’s stock rallies as next-gen blood thinner beats the odds with Phase 3 win
#win Bayer#high-profile failures#stock rallies#next-gen blood#blood thinner
Novo Nordisk's semaglutide misses in closely-watched Alzheimer’s trials
#Novo Nordisk#closely-watched Alzheimer#long shot#long shots#Nordisk semaglutide
Craig Crews, Mikael Dolsten raise $32M for Quarry Thera
#Mikael Dolsten#Quarry Thera#Craig Crews#Dolsten raise#Mikael
Nobel laureate Carolyn Bertozzi to rejoin Lilly board
#Carolyn Bertozzi#Eli Lilly#SEC filing#Friday evening#evening SEC
Makary’s user fee comments; M&A activity stays hot; A new use for prime editing; and more
#Endpoints Weekly#fee comments#stays hot#prime editing#user fee
Top Makary aide Jain-Nagpal remains at the FDA after White House pushback
#White House#Commissioner Marty#FDA Commissioner#Marty Makary#Top Makary
AstraZeneca to onshore rare disease portfolio as part of its $50B pledge to the US
#announced Friday#billion pledge#onshore rare#rare disease#disease portfolio
Teva loses IRA drug pricing challenge in DC federal court
#federal court#loses IRA#IRA drug#Medicare negotiations#pharma industry
Sarepta ends Elevidys trial with Hansa's pre-treatment; Some pipeline cuts at Moderna
#Blue Lake#Inhibikase Therapeutics#Olema Oncology#Elevidys trial#Hansa Biopharma
FDA investigates child death potentially related to Takeda's enzyme replacement therapy
#FDA investigates#blood disorder#Takeda enzyme#potentially related#investigates child
Novo, Lilly begin to sell obesity medications directly to employers
#Novo Nordisk#Eli Lilly#employers Building#Lilly begin#weight loss
Lilly becomes first $1 trillion pharma company
#Eli Lilly#company Eli#Lilly market#pharma company#briefly reached
Contineum's J&J-partnered drug fails Phase 2 multiple sclerosis trial
#Thursday afternoon#fails Phase#Therapeutics reported#multiple sclerosis#J-partnered drug
GSK, AnaptysBio enter legal battle over decade-old Jemperli licensing deal
#decade-old Jemperli#drug Jemperli#Jemperli licensing#subsidiary Tesaro#cancer drug
Jeff Bluestone, Stephen Dilly talk CEO handoff, what’s next for Sonoma; Scott Gottlieb's next move
#Stephen Dilly#Scott Gottlieb#Jeff Bluestone#Sonoma Biotherapeutics#CEO handoff
Under RFK Jr., vaccine use slides while suspicion rises
#vaccine revenue#suspicion rises#flu season#federal health#health officials